MedTrace Logo

Association of Circulating ACE2 Levels With COVID-19

NCT05205707 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 261

Last updated 2022-02-08

No results posted yet for this study

Summary

COVID-19 cases are rising substantially in Jordan. Since this is a novel virus, there is still much to be investigated surrounding its pathophysiology in order to attempt to find suitable treatments or better decision-making in the prognosis of the disease. This project aims to identify if soluble angiotensin-converting enzyme (ACE2) can be used as a prognostic factor for COVID-19 severity, which will allow clinicians to manage COVID-19 cases more efficiently. ACE2 is of interest since the coronavirus enters host cells through ACE2 receptors. It can slo be hypothesized that the irus may also bind to soluble ACE2, but without mediating its effects. It si, therefore, expected that those with higher levels of ACE2 would more likely have milder disease. This can potentially help improve survival rate, allowing clinicians to identify the higher-risk patients and monitoring them more closely.

Conditions

  • COVID-19
  • COVID-19 Respiratory Infection

Interventions

DIAGNOSTIC_TEST

ACE serum levels

Circulating ACE2 level will be measured

Sponsors & Collaborators

  • Jordan University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-01-20
Completion
2022-01-21

Countries

  • Jordan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05205707 on ClinicalTrials.gov